211 related articles for article (PubMed ID: 33733980)
1. A multicenter, open-label study of netarsudil for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension in a real-world setting.
Zaman F; Gieser SC; Schwartz GF; Swan C; Williams JM
Curr Med Res Opin; 2021 Jun; 37(6):1011-1020. PubMed ID: 33733980
[TBL] [Abstract][Full Text] [Related]
2. Fixed-Dose Combination of Netarsudil and Latanoprost in Ocular Hypertension and Open-Angle Glaucoma: Pooled Efficacy/Safety Analysis of Phase 3 MERCURY-1 and -2.
Asrani S; Bacharach J; Holland E; McKee H; Sheng H; Lewis RA; Kopczynski CC; Heah T
Adv Ther; 2020 Apr; 37(4):1620-1631. PubMed ID: 32166538
[TBL] [Abstract][Full Text] [Related]
3. Rho kinase inhibitor for primary open-angle glaucoma and ocular hypertension.
Clement Freiberg J; von Spreckelsen A; Kolko M; Azuara-Blanco A; Virgili G
Cochrane Database Syst Rev; 2022 Jun; 6(6):CD013817. PubMed ID: 35686679
[TBL] [Abstract][Full Text] [Related]
4. Comparison of safety and efficacy of Netarsudil 0.02% and Bimatoprost 0.01% monotherapy and combination therapy in primary open-angle glaucoma and ocular hypertension.
Shahid S; Rizvi SWA; Khan AA; Ashraf H; Akhter A
Indian J Ophthalmol; 2024 Mar; 72(3):427-431. PubMed ID: 38146971
[TBL] [Abstract][Full Text] [Related]
5. Phase 2 Randomized Clinical Study of Netarsudil Ophthalmic Solution in Japanese Patients with Primary Open-Angle Glaucoma or Ocular Hypertension.
Araie M; Sugiyama K; Aso K; Kanemoto K; Kothapalli K; Kopczynski C; Senchyna M; Hollander DA
Adv Ther; 2021 Apr; 38(4):1757-1775. PubMed ID: 33629227
[TBL] [Abstract][Full Text] [Related]
6. Pooled Efficacy and Safety Profile of Netarsudil Ophthalmic Solution 0.02% in Patients With Open-angle Glaucoma or Ocular Hypertension.
Singh IP; Fechtner RD; Myers JS; Kim T; Usner DW; McKee H; Sheng H; Lewis RA; Heah T; Kopczynski CC
J Glaucoma; 2020 Oct; 29(10):878-884. PubMed ID: 32826769
[TBL] [Abstract][Full Text] [Related]
7. Once-Daily Netarsudil/Latanoprost Fixed-Dose Combination for Elevated Intraocular Pressure in the Randomized Phase 3 MERCURY-2 Study.
Walters TR; Ahmed IIK; Lewis RA; Usner DW; Lopez J; Kopczynski CC; Heah T;
Ophthalmol Glaucoma; 2019; 2(5):280-289. PubMed ID: 32672669
[TBL] [Abstract][Full Text] [Related]
8. Once-Daily Netarsudil Versus Twice-Daily Timolol in Patients With Elevated Intraocular Pressure: The Randomized Phase 3 ROCKET-4 Study.
Khouri AS; Serle JB; Bacharach J; Usner DW; Lewis RA; Braswell P; Kopczynski CC; Heah T;
Am J Ophthalmol; 2019 Aug; 204():97-104. PubMed ID: 30862500
[TBL] [Abstract][Full Text] [Related]
9. MERCURY-3: a randomized comparison of netarsudil/latanoprost and bimatoprost/timolol in open-angle glaucoma and ocular hypertension.
Stalmans I; Lim KS; Oddone F; Fichtl M; Belda JI; Hommer A; Laganovska G; Schweitzer C; Voykov B; Zarnowski T; Holló G
Graefes Arch Clin Exp Ophthalmol; 2024 Jan; 262(1):179-190. PubMed ID: 37615697
[TBL] [Abstract][Full Text] [Related]
10. Netarsudil/Latanoprost Fixed-Dose Combination for Elevated Intraocular Pressure: Three-Month Data from a Randomized Phase 3 Trial.
Asrani S; Robin AL; Serle JB; Lewis RA; Usner DW; Kopczynski CC; Heah T;
Am J Ophthalmol; 2019 Nov; 207():248-257. PubMed ID: 31229466
[TBL] [Abstract][Full Text] [Related]
11. Long-term Safety and Ocular Hypotensive Efficacy Evaluation of Netarsudil Ophthalmic Solution: Rho Kinase Elevated IOP Treatment Trial (ROCKET-2).
Kahook MY; Serle JB; Mah FS; Kim T; Raizman MB; Heah T; Ramirez-Davis N; Kopczynski CC; Usner DW; Novack GD;
Am J Ophthalmol; 2019 Apr; 200():130-137. PubMed ID: 30653957
[TBL] [Abstract][Full Text] [Related]
12. A Randomized, Phase 2 Study of 24-h Efficacy and Tolerability of Netarsudil in Ocular Hypertension and Open-Angle Glaucoma.
Peace JH; McKee HJ; Kopczynski CC
Ophthalmol Ther; 2021 Mar; 10(1):89-100. PubMed ID: 33244711
[TBL] [Abstract][Full Text] [Related]
13. Netarsudil monotherapy as the initial treatment for open-angle glaucoma and ocular hypertension in Indian patients: A real-world evaluation of efficacy and safety.
Mathur MC; Ratnam PV; Saikumar SJ; John M; Ravishankar S; Dinesh MB; Chandil P; Pahuja K; Cherlikar V; Wadhwani S; Bendale P; Hazari A; Mishra R; Deshmukh S; Achlerkar RR; Shah DT; Hingorani C; Shah K; Topiwala P; Jani S; Rana VG; Majumdar NK; Chakrabarti D; Dey R; Halder D; Choudhury S; Kumar A; Das S; Nanda AK; Kumar VB; Dubey R; Kamdar GA; Pandey A; Kishanpuria S; Srivastava RM; Singh P; Verma SK; Sharma N; Gupta R
Indian J Ophthalmol; 2023 Jun; 71(6):2500-2503. PubMed ID: 37322670
[TBL] [Abstract][Full Text] [Related]
14. Two Phase 3 Clinical Trials Comparing the Safety and Efficacy of Netarsudil to Timolol in Patients With Elevated Intraocular Pressure: Rho Kinase Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2).
Serle JB; Katz LJ; McLaurin E; Heah T; Ramirez-Davis N; Usner DW; Novack GD; Kopczynski CC;
Am J Ophthalmol; 2018 Feb; 186():116-127. PubMed ID: 29199013
[TBL] [Abstract][Full Text] [Related]
15. One Year of Netarsudil and Latanoprost Fixed-Dose Combination for Elevated Intraocular Pressure: Phase 3, Randomized MERCURY-1 Study.
Brubaker JW; Teymoorian S; Lewis RA; Usner D; McKee HJ; Ramirez N; Kopczynski CC; Heah T
Ophthalmol Glaucoma; 2020; 3(5):327-338. PubMed ID: 32768361
[TBL] [Abstract][Full Text] [Related]
16. Netarsudil ophthalmic solution 0.02% for the treatment of patients with open-angle glaucoma or ocular hypertension.
Kopczynski CC; Heah T
Drugs Today (Barc); 2018 Aug; 54(8):467-478. PubMed ID: 30209441
[TBL] [Abstract][Full Text] [Related]
17. Experience with netarsudil 0.02% and latanoprostene bunod 0.024% as adjunctive therapy for glaucoma.
Mehta AA; Kanu LN; Sood-Mendiratta S; Quinones R; Hawkins A; Lehrer RA; Malhotra K; Papas R; Hillman D; Wilensky JT; Aref AA; Vajaranant TS; Edward DP
Eur J Ophthalmol; 2022 Jan; 32(1):322-326. PubMed ID: 33653172
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness and Tolerability of Netarsudil in Combination with Other Ocular Hypotensive Agents.
Prager AJ; Tang M; Pleet AL; Petito LC; Tanna AP
Ophthalmol Glaucoma; 2021; 4(6):597-603. PubMed ID: 33838336
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Netarsudil/Latanoprost Therapy with Latanoprost Monotherapy for Lowering Intraocular Pressure: A Systematic Review and Meta-analysis.
Lee JW; Ahn HS; Chang J; Kang HY; Chang DJ; Suh JK; Lee H
Korean J Ophthalmol; 2022 Oct; 36(5):423-434. PubMed ID: 35989070
[TBL] [Abstract][Full Text] [Related]
20. Netarsudil Improves Trabecular Outflow Facility in Patients with Primary Open Angle Glaucoma or Ocular Hypertension: A Phase 2 Study.
Sit AJ; Gupta D; Kazemi A; McKee H; Challa P; Liu KC; Lopez J; Kopczynski C; Heah T
Am J Ophthalmol; 2021 Jun; 226():262-269. PubMed ID: 33524367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
